A Setting Focus Overdose Prevention Intervention (Oasis)

May 19, 2026 updated by: Johns Hopkins Bloomberg School of Public Health

A Geospatial Analysis of Hotspots and Targeted Injection Settings Pilot Intervention for HIV Prevention Among People Who Inject Drugs in Baltimore, Maryland

A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a pilot of an injection setting targeted peer-driven intervention to reduce HIV/HCV transmission and overdose risk behaviors. Participants will be randomized to conditions: 1) Peer education and stocking of semi-public injection settings (SPIS) with risk reduction materials, and the standard of care. Based on their SPIS use, 120 index PWID participants will be selected.

A conceptual model for the intervention: The conceptual model is based on social influence, social network, and social cognitive theory. The prior work delineated social influence mechanisms. It is expected that training and modeling of effective communication skills will increase the occurrence of conversations on HIV/HCV and overdose prevention. These conversations will then alter perceived descriptive and prescriptive social norms of risk behaviors. The prior work is being enhanced by increasing the availability of risk reduction materials as well as the cuing and modeling risk reduction behaviors in risk settings. It has been found that PWID are motivated to conduct peer education; it enhances their status and provides them a prosocial role in the community. It is hypothesized that peer outreach and supply of materials to SPIS will lead to reduced sharing of injection equipment and increased naloxone availability.

Study Type

Interventional

Enrollment (Estimated)

285

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Maryland
      • Baltimore, Maryland, United States, 21205
        • Recruiting
        • Lighthouse Studies at Peer Point
        • Contact:
        • Contact:
          • Melissa Davey-Rothwell, PhD
          • Phone Number: 410-614-5854
          • Email: mdavey1@jhu.edu
        • Principal Investigator:
          • Carl Latkin, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Current drug user (opioid use in the prior two weeks)

Exclusion Criteria:

  • Any mental or physical health impairment that impedes ability to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental
behavioral training with 6 sessions
Behavioral: HIV, HCV and overdose prevention
HIV, HCV and overdose prevention
Active Comparator: comparison
Attention control
Behavioral: HIV, HCV and overdose prevention
HIV, HCV and overdose prevention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overdose prevention
Time Frame: 6 months
Frequency of carrying naloxone
6 months
HIV/HCV prevention
Time Frame: 6 months
Frequency of using used cookers
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overdose behaviors
Time Frame: 6 months
Frequency of testing drugs before using
6 months
Overdose behaviors 2
Time Frame: 6 months
Frequency of talking about overdose prevention
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Johns Hopkins Bloomberg School of Public Health

Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Carl Latkin, PhD, Johns Hopkins Bloomberg School of Public Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 30, 2022

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

May 30, 2027

Study Registration Dates

First Submitted

March 30, 2022

First Submitted That Met QC Criteria

April 8, 2022

First Posted (Actual)

April 11, 2022

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 19, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • R01DA050470 (U.S. NIH Grant/Contract)
  • IRB00019139 (Other Identifier: JHSPH IRB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe